Therapeutics for HIV-1 reactivation from latency

Current Opinion in Virology

Volumn 3, Issue 4, 2013, Pages 394-401

  Sgarbanti, Marco ^a   Battistini, Angela ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIRETROVIRUS AGENT; AZACITIDINE; BELINOSTAT; BRYOSTATIN 1; DISULFIRAM; GIVINOSTAT; HETEROCHROMATIN PROTEIN 1; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HOST FACTOR; INTERFERON REGULATORY FACTOR 1; METHYLTRANSFERASE INHIBITOR; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; OXAMFLATIN; PANOBINOSTAT; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN KINASE C ACTIVATOR; ROMIDEPSIN; VALPROIC ACID; VORINOSTAT;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CPG ISLAND; CYTOPATHOGENIC EFFECT; DNA METHYLATION; EPILEPSY; GENE ACTIVATION; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HISTONE ACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LATENT VIRUS INFECTION; LEUKEMIA; LONG TERMINAL REPEAT; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; VIRUS GENE; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 84885075354     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.06.001     Document Type: Review

References (81)

1. Esté JA, Cihlar T: Current status and challenges of antiretroviral research and therapy. Antiviral Res 2010, 85:25-33.
2. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF: In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995, 1:1284-1290.
3. Eisele E, Siliciano RF: Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012, 37:377-388. The authors propose definitions for key terms in eradication research and viral reservoirs.
4. Doyle T, Geretti AM: Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis 2012, 25:17-25.
5. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+T cells. Nat Med 2003, 9:727-728. (Pubitemid 36749221)
6. Rong L, Perelson AS: Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci 2009, 217:77-87.
7. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009, 15:893-900. This seminal paper dissects, for the first time, the nature of HIV-1 reservoir among different CD4 subsets and demonstrates that two principal mechanisms are responsible for the maintenance of these reservoirs.
8. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O'Shea A, Callender M, Spivak A, Brennan T et al.: Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009, 106:9403-9408.
9. Deeks SG, Autran B, Berkhout B, Benkirane M, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A et al.: Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 2012, 12:607-614. A comprehensive analysis from 'The International AIDS Society Scientific Working Group on HIV Cure' of major hurdles that scientific community faces in looking for a HIV cure. The paper also describes the seven key priorities identified by the IAS for HIV cure research.
10. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, Chomont N: HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329:174-180.
11. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA et al.: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005, 191:1410-1418. (Pubitemid 40563351)
12. Lewis MG, DaFonseca S, Chomont N, Palamara AT, Tardugno M, Mai A, Collins M, Wagner WL, Yalley-Ogunro J, Greenhouse J et al.: Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 2011, 25:1347-1356.
13. Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM: Prospects for treatment of latent HIV. Clin Pharmacol Ther 2013, 93:46-56.
14. Xing S, Siliciano RF: Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 2012 http://dx.doi.org/10.1016/jdrudis. 2012.12.008. pii: S1359- 6446(12)00431-X (Dec 25, Epub ahead of print).
15. Margolis DM, Hazuda DJ: Combined approaches for HIV cure. Curr Opin HIV AIDS 2013, 8:230-235.
16. Massanella M, Martinez-Picado J, Blanco J: Attacking the HIV reservoir from the immune and viral perspective. Curr HIV/AIDS Rep 2013, 10:33-41.
17. Brady T, Agosto LM, Malani N, Berry CC, O'Doherty U, Bushman F: HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009, 23:1461-1471.
18. Shan L, Yang HC, Rabi SA, Bravo HC, Shroff NS, Irizarry RA, Zhang H, Margolick JB, Siliciano JD, Siliciano RF: Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol 2011, 85:5384-5393.
19. Hakre S, Chavez L, Shirakawa K, Verdin E: Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 2011, 6:19-24.
20. Donahue DA, Wainberg MA: Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology 2013, 10:11 http://dx.doi.org/10.1186/1742-4690-10-11.
21. Karn J: The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS 2011, 6:4-11.
22. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM: A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009, 83:4749-4756.
23. Margolis DM: Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS 2011, 6:25-29 http://dx.doi.org/10.1097/COH.0b013e328341242d.
24. Marsili G, Remoli AL, Sgarbanti M, Perrotti E, Fragale A, Battistini A: HIV-1, interferon and the interferon regulatory factor system: An interplay between induction, antiviral responses and viral evasion. Cytokine Growth Factor Rev 2012, 23:255-270.
25. Remoli AL, Marsili G, Battistini A, Sgarbanti M: The development of immune-modulating compounds to disrupt HIV latency. Cytokine Growth Factor Rev 2012, 23:159-172.
26. Fragale A, Stellacci E, Ilari R, Remoli AL, Lanciotti A, Perrotti E, Shytaj I, Orsatti R, Lawrence HR, Lawrence NJ et al.: Critical role of IRF-8 in negative regulation of TLR3 expression by Src homology 2 domain-containing protein tyrosine phosphatase- 2 activity in human myeloid dendritic cells. J Immunol 2011, 186:1951-1962.
27. Sgarbanti M, Borsetti A, Moscufo N, Bellocchi MC, Ridolfi B, Nappi F, Marsili G, Marziali G, Coccia EM, Ensoli B, Battistini A: Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J Exp Med 2002, 195:1359-1370. (Pubitemid 34564337)
28. Sgarbanti M, Remoli AL, Marsili G, Ridolfi B, Borsetti A, Perrotti E, Orsatti R, Ilari R, Sernicola L, Stellacci E et al.: IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J Virol 2008, 82:3632-3641. (Pubitemid 351429939)
29. Munier S, Delcroix-Genete D, Carthagé na L, Gumez A, Hazan U: Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency. Retrovirology 2005, 2:73.
30. du Ché né I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable- Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P et al.: Suv39H1 and HP1gamma are responsible for chromatinmediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 2007, 26:424-435. (Pubitemid 46160943)
31. Imai K, Togami H, Okamoto T: Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 2010, 285:16538-16545.
32. Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J: Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 2011, 85:9078-9089.
33. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, Verdin E, Olive D, Van Lint C, Hejnar J et al.: CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009, 5:e1000554.
34. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E: Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009, 5:e1000495.
35. Blazkova J, Murray D, Justement JS, Funk EK, Nelson AK, Moir S, Chun TW, Fauci AS: Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol 2012, 86:5390-5392.
36. Taube R, Peterlin M: Lost in transcription: molecular mechanisms that control HIV latency. Viruses 2013, 5:902-927.
37. Budhiraja S, Famiglietti M, Bosque A, Planelles V, Rice AP: Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol 2013, 87:1211-1220.
38. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB: HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010, 11:419-426.
39. Brasier AR, Tian B, Jamaluddin M, Kalita MK, Garofalo RP, Lu M: RelA Ser276 phosphorylation-coupled Lys310 acetylation controls transcriptional elongation of inflammatory cytokines in respiratory syncytial virus infection. J Virol 2011, 85:11752-11769.
40. Duverger A, Wolschendorf F, Zhang M, Wagner F, Hatcher B, Jones J, Cron RQ, van der Sluis RM, Jeeninga RE, Berkhout B et al.: An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol 2013, 87:2264-2277.
41. Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O: Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-kappaB activity. J Virol 2012, 86:4548-4558.
42. Zhou M, Huang K, Jung KJ, Cho WK, Klase Z, Kashanchi F, Pise-Masison CA, Brady JN: Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29. J Virol 2009, 83:1036-1044.
43. Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E: Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013. pii: S0966-842X(13)00035-8.
44. Ververis K, Hiong A, Karagiannis TC, Licciardi PV: Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013, 7:47-60.
45. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC et al.: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485. This paper constitute the proof-of-concept that a single dose of the HDAC inhibitor Vorinistat can disrupt latent infection within a detectable proportion of the reservoir of latent resting CD4+T cells in patients on c-ART.
46. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N et al.: Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012, 13:291-296. Large cross-over study showing that the weak HDAC inhibitor valproic acid is ineffective in reducing the resting CD4 reservoir in virally suppressed patients.
47. Matalon S, Palmer BE, Nold MF, Furlan A, Kassu A, Fossati G, Mascagni P, Dinarello CA: The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010, 54:1-9.
48. Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, Dinarello CA: Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 2011, 17:353-362.
49. Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, Dinarello C, Ostergaard L, Tolstrup M: Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013:9. (Epub ahead of print).
50. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N: Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 2011, 286:22211-22218. The authors highlight the importance of HDAC3 in HIV-1 latency.
51. Yin H, Zhang Y, Zhou X, Zhu H: Histonedeacetylase inhibitor oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep 2011, 38:5071-5078.
52. Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N, Ochiai K, Okamoto T: Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett 2011, 585:1103-1111.
53. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002, 62:4916-4921. (Pubitemid 34984414)
54. Sweet MJ, Shakespear MR, Kamal NA, Fairlie D: HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol 2012, 90:14-22.
55. Kanwar B, Favre D, McCune JM: Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS 2010, 5:151-157.
56. Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I: The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett 2011, 585:3549-3554.
57. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C et al.: Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 2012, 26:1473-1482.
58. Fernandez G, Zeichner SL: Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J 2010, 7:266-276.
59. Laska MJ, Nissen KK, Nexø BA: (Some) cellular mechanisms influencing the transcription of human endogenous retrovirus, HERV-Fc1. PLoS ONE 2013, 8:e53895.
60. Sanchez-Duffhues G, Vo MQ, Perez M, Calzado MA, Moreno S, Appendino G, Muñ oz E: Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs. Curr Drug Targets 2011, 12:348-356.
61. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V et al.: Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 2009, 4:e6093.
62. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, Nagarkatti P, Nagarkatti M, Chauhan A: Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE 2010, 5:e111.
63. Perez M, de Vinuesa AG, Sanchez-Duffhues G et al.: Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 2010, 8:418-429.
64. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM: HDAC inhibitors that release positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem 2013. (Mar 28, Epub ahead of print).
65. DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA: Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 2012, 4:705-710. The paper describes the successful chemical synthesis of a new family of designed bryostatin analogs that are up to 1000-fold more potent in inducing latent HIV expression than prostratin.
66. Morgan RJ Jr, Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz HJ, Doroshow JH: Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium study. Invest New Drugs 2012, 30:723-728.
67. Contreras X, Barboric M, Lenasi T, Peterlin BM: HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog 2007, 3:1459-1469. (Pubitemid 350085610)
68. Choudhary SK, Archin NM, Margolis DM: Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis 2008, 197:1162-1170. (Pubitemid 351590052)
69. Yang HC, Sifei X, Liang S, O'Connell K, Dinoso J, Shen A, Zhou Y, Shrum CK, Han Y, Liu JO et al.: Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009, 119:3473-3486.
70. Huang B, Yang XD, Zhou MM, Ozato K, Chen LF: Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol 2009, 29:1375-1387.
71. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M: BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012, 92:1147-1154. These different groups provided evidences that BRD4 may represent a new 'druggable' target to reverse latency.
72. Zhu J, Gaiha GD, John SP, Pertel T, Chin CR, Gao G, Qu H, Walker BD, Elledge SJ, Brass AL: Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2012, 2:807-816.
73. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM: Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 2012, 287:36609-36616.
74. Li Z, Guo J, Wu Y, Zhou Q: The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 2013, 41:277-287.
75. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE et al.: BET bromodomaintargeting compounds reactivate HIV from latency via a Tatindependent mechanism. Cell Cycle 2013, 12:452-462.
76. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, Bhat S, Zhang H, Margolick JB, Quinn TC et al.: Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011, 85:6060-6064.
77. Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N: Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog (PTEN). AIDS 2013, 27:F7-F11.
78. Xing S, Bhat S, Shroff NS, Zhang H, Lopez JA, Margolick JB, Liu JO, Siliciano RF: Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Antimicrob Chemother 2012, 67:398-403.
79. Micheva-Viteva S, Kobayashi Y, Edelstein LC, Pacchia AL, Lee HL, Graci JD, Breslin J, Phelan BD, Miller LK, Colacino JM et al.: Highthroughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a HDAC inhibitor. J Biol Chem 2011, 286:21083-21091.
80. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF: Stimulation of HIV-1- specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501.
81. Mitsuyasu R: Curing HIV: lessons from cancer therapy. Curr Opin HIV AIDS 2013, 8:224-229.